Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM.
Morita
H
H
Oki
Y
Y
Ito
T
T
Ohishi
H
H
Suzuki
S
S
Nakamura
H
H
D000284:Administration, Oral; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D002839:Chromans / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood*; D005951:Glucose Tolerance Test; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D008657:Metabolic Clearance Rate; D000077205:Pioglitazone; D012016:Reference Values; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D000077288:Troglitazone
D001786:Blood Glucose; D002839:Chromans; D007004:Hypoglycemic Agents; D007328:Insulin; D013844:Thiazoles; D045162:Thiazolidinediones; D003907:Dexamethasone; D000077288:Troglitazone; D000077205:Pioglitazone